CRDL
Cardiol Therapeutics, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$1.10
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 52.7K | — | — | 187.4K | 162.2K |
| Gross Profit | (52.7K) | — | — | (187.4K) | (162.2K) |
| Operating Expenses | |||||
| R&D Expense | 17.0M | 14.0M | 14.0M | 10.7M | 14.0M |
| SG&A Expense | 22.1M | 20.2M | 25.9M | 11.6M | 16.3M |
| General & Admin Expense | 17.4M | 20.2M | 25.9M | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 51.5K | 102.0K | 373.1K | — | — |
| Total Operating Expenses | 39.2M | 34.3M | 40.3M | 22.3M | 30.3M |
| Cost and Expenses | 39.2M | 34.3M | 40.3M | 22.5M | 30.5M |
| Operating Income (EBIT) | (39.2M) | (34.3M) | (40.3M) | (22.5M) | (30.5M) |
| Non-Operating | |||||
| Interest Income | 784.8K | 726.4K | 1.2M | 2.0M | 1.2M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 784.8K | 726.4K | 1.2M | 2.0M | 1.2M |
| Other Non-Op Income/Expense | 2.3M | 497.4K | 3.6M | 1.3M | 7.7M |
| Non-Operating Income (excl Interest) | (2.3M) | (497.4K) | (3.6M) | (1.3M) | (7.7M) |
| EBT (Pre-Tax Income) | (37.0M) | (33.8M) | (36.7M) | (21.2M) | (22.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (36.7M) | (33.8M) | (36.7M) | (21.2M) | (22.8M) |
| Earnings from Cont. Ops | (37.0M) | (33.8M) | (36.7M) | (21.2M) | (22.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (36.7M) | (33.8M) | (36.7M) | (21.2M) | (22.8M) |
| Per Share | |||||
| Basic EPS | ($0.36) | ($0.39) | ($0.51) | ($0.44) | ($0.49) |
| Diluted EPS | ($0.36) | ($0.39) | ($0.51) | ($0.44) | ($0.49) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 114.9M | 87.0M | 71.6M | 64.5M | 62.5M |
| Diluted Shares Outstanding | 114.9M | 87.0M | 71.6M | 64.5M | 62.5M |
| Profitability Metrics | |||||
| EBITDA | (36.9M) | (33.7M) | (36.3M) | (21.0M) | (22.6M) |
| D&A | 89.8K | 102.0K | 373.1K | 248.4K | 219.9K |
| EBIT | (37.0M) | (33.8M) | (36.7M) | (21.2M) | (22.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026